These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33397584)

  • 1. Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival.
    Al-Ahmadi A; Ardeshir-Larijani F; Fu P; Cao S; Lipka MB; Dowlati A; Bruno DS
    Clin Lung Cancer; 2021 Jan; 22(1):16-22.e1. PubMed ID: 33397584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between race and survival of patients with non--small-cell lung cancer in the United States veterans affairs population.
    Ganti AK; Subbiah SP; Kessinger A; Gonsalves WI; Silberstein PT; Loberiza FR
    Clin Lung Cancer; 2014 Mar; 15(2):152-8. PubMed ID: 24361249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer.
    Arrieta O; Aviles-Salas A; Orozco-Morales M; Hernández-Pedro N; Cardona AF; Cabrera-Miranda L; Barrios-Bernal P; Soca-Chafre G; Cruz-Rico G; Peña-Torres ML; Moncada-Claudio G; Ramirez-Tirado LA
    Cancer Med; 2020 Apr; 9(7):2390-2402. PubMed ID: 32043750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
    Reckamp KL; Patil T; Kirtane K; Rich TA; Espenschied CR; Weipert CM; Raymond VM; Santana-Davila R; Doebele RC; Baik CS
    Clin Lung Cancer; 2020 Nov; 21(6):545-552.e1. PubMed ID: 32665165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
    Rice SJ; Liu X; Hyland V; Liu Z; Belani CP
    Lung Cancer; 2020 Mar; 141():97-100. PubMed ID: 31986371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.
    Cheng H; Hosgood HD; Deng L; Ye K; Su C; Sharma J; Yang Y; Halmos B; Perez-Soler R
    Clin Lung Cancer; 2020 Mar; 21(2):177-185. PubMed ID: 31420240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States.
    Ramalingam S; Dinan MA; Crawford J
    J Thorac Oncol; 2018 Dec; 13(12):1842-1850. PubMed ID: 30312680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial and Ethnic Disparities in Lung Adenocarcinoma Survival: A Competing-Risk Model.
    Wu X; Wang Y; Lin X; Wang Z; Xu J; Lv W; Hu J
    Clin Lung Cancer; 2020 May; 21(3):e171-e181. PubMed ID: 31787547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparate outcomes in nonsmall cell lung cancer by immigration status.
    Chau B; Ituarte PH; Shinde A; Li R; Vazquez J; Glaser S; Massarelli E; Salgia R; Erhunmwunsee L; Ashing K; Amini A
    Cancer Med; 2021 Apr; 10(8):2660-2667. PubMed ID: 33734614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
    Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J
    J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
    Bergqvist M; Christensen HN; Wiklund F; Bergström S
    Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities.
    Begnaud A; Yang P; Robichaux C; Rubin N; Kratzke R; Melzer A; Aliferis C; Jacobson P
    Clin Lung Cancer; 2020 May; 21(3):e164-e168. PubMed ID: 31759888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
    Lee K; Kim D; Yoon S; Lee DH; Kim SW
    Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
    Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
    Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.